Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals stock closes 10% higher at TWD 70.40

Published on 11/09/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway Biopharmaceuticals stock develops drug candidates for aesthetic medicine and chronic inflammation. CBL-514 remains in Phase 2 development.

Caliway Biopharmaceuticals stock snapshot

Caliway develops drug candidates for aesthetic medicine and chronic inflammation.
CBL-514 is in Phase 2 trials for nonsurgical fat reduction and Dercum's disease.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals stock closed at 70.40 Taiwan dollars on the Taiwan Stock Exchange at 1:30:19 p.m. GMT+8 on Monday, November 9, 2026, 10.00 percent above the TWSE close of Friday, November 6, according to Yahoo Finance and the historical table from Investing.com.

Pipeline Keeps Focus On CBL-514

Yahoo Finance describes Caliway Biopharmaceuticals as a developer of medicines for aesthetic medicine and chronic inflammation. Its lead candidate CBL-514 is being tested for nonsurgical fat reduction and Dercum's disease, while the company also develops CBA-539 in preclinical programs.

The session's gain provides a market reference but does not establish a clinical outcome or regulatory approval. For investors, progress in CBL-514 development remains the central company-specific factor alongside execution of the clinical program.